Analysed ALIGOS THERAPEUTICS INC (ALGS:NASDAQ) News Sources
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
23-02-2026
yahoo.com
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
26-02-2026
yahoo.com
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
05-03-2026
yahoo.com
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
14-04-2026
yahoo.com
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
16-04-2026
yahoo.com
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24-04-2026
yahoo.com
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
30-04-2026
yahoo.com
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
07-05-2026
yahoo.com
What is the current price of ALIGOS THERAPEUTICS INC (ALGS:NASDAQ)?
The current price of ALIGOS THERAPEUTICS INC (ALGS:NASDAQ) is $5.79.
ALIGOS THERAPEUTICS INC (ALGS:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALIGOS THERAPEUTICS INC (ALGS:NASDAQ) since the previous trading day is $0.19.
ALIGOS THERAPEUTICS INC (ALGS:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALIGOS THERAPEUTICS INC (ALGS:NASDAQ) since the previous trading day is 3.3929%.
What is the most recent average sentiment score for ALIGOS THERAPEUTICS INC (ALGS:NASDAQ)?
The most recent average sentiment score for ALIGOS THERAPEUTICS INC (ALGS:NASDAQ) is 85 out of 100.
What is the most recent average sentiment for ALIGOS THERAPEUTICS INC (ALGS:NASDAQ)?
The most recent sentiment for ALIGOS THERAPEUTICS INC (ALGS:NASDAQ) is .
SEC-8K** Filing Available For ALIGOS THERAPEUTICS INC (ALGS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.